Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Tagrisso“
Suchtreffer
Begriffe & Kennungen
Tagrisso
Eintrag öffnenTagrisso · 4.1 Therapeutic indications · 1
Eintrag öffnenTagrisso · 4.3 Contraindications · 1
Eintrag öffnenTagrisso · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenTagrisso · 4.3 · St. John’s Wort should not be used together with TAGRISSO (see section 4.5).
Eintrag öffnenTagrisso · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenTagrisso · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenTagrisso · 4.5 · 8 In a clinical PK study, co-administration of TAGRISSO with rosuvastatin (sensitive BCRP substrate) increased
Eintrag öffnenTagrisso · 4.5 · Active substances that may decrease osimertinib plasma concentrations
Eintrag öffnenTagrisso · 4.5 · Active substances that may increase osimertinib plasma concentrations
Eintrag öffnenTagrisso · 4.5 · Active substances whose plasma concentrations may be altered by TAGRISSO
Eintrag öffnenTagrisso · 4.5 · Based on in vitro studies, osimertinib is a competitive inhibitor of BCRP transporters.
Eintrag öffnenTagrisso · 4.5 · Effect of gastric acid reducing active substances on osimertinib
Eintrag öffnenTagrisso · 4.5 · In a clinical PK study, co-administration of TAGRISSO with simvastatin (sensitive CYP3A4 substrate) decreased
Eintrag öffnenTagrisso · 4.5 · In a clinical Pregnane X Receptor (PXR) interaction study, co-administration of TAGRISSO with fexofenadine (P-
Eintrag öffnenTagrisso · 4.5 · In a clinical pharmacokinetic study in patients, the steady-state AUC of osimertinib was reduced by 78% when c
Eintrag öffnenTagrisso · 4.5 · In a clinical pharmacokinetic study, co-administration of omeprazole did not result in clinically relevant cha
Eintrag öffnenTagrisso · 4.5 · In vitro studies have demonstrated that the Phase I metabolism of osimertinib is predominantly via CYP3A4 and
Eintrag öffnenTagrisso · 4.5 · Pharmacokinetic interactions
Eintrag öffnenTagrisso · 4.5 · Strong CYP3A4 inducers can decrease the exposure of osimertinib. Osimertinib may increase the exposure of brea
Eintrag öffnen